CMS Administrator Mehmet Oz announced at the PhRMA Forum that the White House aims to codify voluntary drug pricing deals between pharmaceutical companies and the Trump administration into law, highlighting ongoing efforts to lower drug costs. This matters for content creators as it underscores the significance of reporting on health policy changes and their potential impacts on public health and pharmaceutical industry practices.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



